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Refractory lymphomaa b s t r a c t
Objective: Non Hodgkin Lymphomas (NHL)s are a group of malignancies which affect the lymphatic sys-
tem. A significant proportion of NHL patients experience either relapse or failure of treatment which is
called refractory disease. Relapsed or refractory NHL usually have poor prognosis due to shortage of ran-
domized trials comparing efficacy of different treatment protocols to define the optimal salvage
chemotherapy regimen in these cases. In this study, we are trying to define the best salvage chemother-
apy regimen with low toxicity and better quality of life for patients by comparing outcome of 2 salvage
chemotherapy regimens GDP & DHAP.
Patients and methods: 100 patients diagnosed as relapsed or refractory NHL were randomly assigned to
receive either Gemcitabine, Dexamethasone and Cisplatin (GDP) or Dexamethasone, Cytarabine and
Cysplatin (DHAP) for 4 to 6 cycles. Primary endpoints of the study were overall survival and progression
free survival. Secondary endpoints were response to treatment, toxicity profile of each regimen, and qual-
ity of life assessment.
Results: The overall response rate was 70% in GDP group & 64% in DHAP group with no statistically sig-
nificant difference between them (p-value 0.5). There was no significant difference between both groups
regarding toxicity profile except in febrile neutropenia episodes which was much less in GDP group
(p-value 0.04). Quality of life was better in GDP group than DHAP with significant difference (p-value
< 0.05). There was no statistical significant difference between both groups regarding OS or PFS.
Conclusion: GDP is as effective as DHAP for relapsed or refractory lymphoma with less toxicity and better
quality of life.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non Hodgkin Lymphomas (NHL)s are a group of malignancies
which affect the lymphatic system, they result from uncontrolled
monoclonal proliferation of B or T lymphocytes and natural killer
(NK) cells.1
Although aggressive NHLs are characterized by fast growth and
short survival with increasing number of patients being cured by
intensive chemotherapy, a significant proportion of NHL patients
experience either relapse or failure of treatment which is called
refractory disease.2
Relapsed or refractory NHL usually have poor prognosis due to
different biologic and gene expression markers of the disease, drug
resistance and patient related factors which lead to difficulty indefining the optimal salvage chemotherapy regimen in these
cases.3
In developing countries with limited resources as Egypt, high
dose chemotherapy followed by autologous stem cell transplant
(ASCT) is not always an option of treatment in relapsed and refrac-
tory lymphomas due to low number of transplant centers across
the country, long waiting lists and limited resources.
So, in this study we are trying to define the best salvage
chemotherapy regimen with low toxicity and better quality of life
to be offered to this group of patients with poor prognosis.2. Patients and methods
This prospective randomized study was conducted at Clinical
Hematology Unit, Internal Medicine Department and Medical
oncology department, Faculty of Medicine, Assiut University,
between January 2013 and December 2016. Eligibility criteria were
defined as all patients more than 18 years of age with histologically
Table 1
Patients characteristics.
Variables GDP group (n = 50) DHAP group (n = 50)
Age (years)
Median (range) 40 (24–65) 53 (22–69)
Sex
Male 27 (54) 32 (64)
Female 23 (46) 18 (36)
Constitutional symptoms
Present 30 (60) 32 (64)
Absent 20 (40) 18 (36)
IPI risk factors at the entry
Low and Low-intermediate risk 12 (24) 14 (28)
High-intermediate risk 10 (20) 14 (28)
High risk 28 (56) 22 (44)
Immunophenotype
B- cell 33 (66) 30 (60)
T- cell 17 (34) 20 (40)
Response to previous therapy
Refractory 14 (28) 14 (28)
Relapse < 1 year 23 (46) 20 (40)
Relapse > 1 year 13 (26) 16 (32)
Histology
Diffuse large B cell 24 (48) 22 (44)
Transformed indolent 12 (24) 14 (28)
Follicular 10 (20) 8 (16)
Anaplastic large cell 4 (8) 6 (12)
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or relapsed after one chemotherapy regimen, with measurable
lesion, normal liver and kidney functions and Eastern Cooperative
Oncology Group (ECOG) performance status from zero to two. This
study included one hundred patients who were randomly assigned
to receive either Gemcitabine, Dexamethasone and Cisplatin (GDP)
or Dexamethasone, Cytarabine and Cysplatin (DHAP) for 4 to 6
cycles.
Patients were randomized into 2 groups: Group (A) which con-
sisted of 50 patients who received GDP in the form of Gemcitabine
1000 mg/m2 I.V on days 1&8, Dexamethasone 40 mg I.V on days 1–
4 and Cisplatin 75 mg/m2 I.V on day 1 every 21 days for 4–6 cycles
and Group(B) which consisted of 50 patients who received DHAP in
the form of Dexamethasone 40 mg on days 1–4, Cytarabine 2 g/m2
on days 2&3 and Cisplatin 35 mg/m2 on days 1–3 every 21 days for
4–6 cycles. Ondansteron and dexamethasone were given as
antiemetics before each cycle in both regimens. GDP was given
as an outpatient regimen while DHAP was an inpatient regimen.
All patients in both groups were subjected to full history, com-
plete physical examination, routine baseline laboratory investiga-
tions, excisional lymph node biopsy with immunohistochemistry
to confirm B or T lineage and subtype of NHL, bone marrow aspi-
rate and biopsy with immunophenotyping if indicated and multi-
slice CT scans of chest and abdomen to measure the burden of
the disease.
Complete reevaluation of the patients to assess response to
treatment was done after 2nd, 4th and 6th cycle and response
was determined using International Workshop NHL response crite-
ria.4 Toxicity to treatment was evaluated after the end of every 2
cycles of treatment according to the Common Toxicity Criteria of
the National Cancer Institute.5
Assessment of quality of life was done using the Functional
Assessment of Cancer Therapy (FACT)6 which considers a change
of 10% or more compared to baseline quality of life a meaningful
change and classified into improved, stable and worse.
A written informed consent was obtained from all patients and
approval or research ethics committee of Assiut faculty of medicine
was obtained before the study.
The primary endpoint of the study is to detect overall survival
and progression free survival and the secondary endpoints are
response rate to treatment, toxicity and quality of life assessment.2.1. Statistical analysis
Data entry and data analysis were done using Statistical Pack-
age for Social Science (SPSS). Data were presented as number, per-
centage, mean, standard deviation, standard error, median and
range. Chi-square test was used to compare quantitative variables
between two groups. P-value considered statistically significant
when P < 0.05. Survival curves were done using Kaplan-Meier Sur-









Intention to treat population 50/50 50/50
Overall response rate 35 (70) 32 (64) 0.5
Partial response 20 (40) 18 (36) 0.6
Complete response 15 (30) 14 (28) 0.73. Results
This study included one hundred NHL patients. Fifty patients
received GDP, they were 27 males (54%) & 23 females (46%) with
median age of 40 years (24–65), while DHAP regimen was given
to another 50 patients, 32 males (64%) & 18 females (36%) with
age ranged from 22 to 69 years (Table 1).
In patients who received GDP constitutional symptoms were
present in 30 patients (60%) and were absent in 20 patients
(40%), while in patients received DHAP they were present in 32
patients (64%) and absent in 18 patients (36%).Most of the patients included in the study have high IPI risk fac-
tor with 56% in GDP group and 44% in DHAP group. 33 patients
(66%) were diagnosed as B-NHL in GDP group and 30 patients
(60%) in DHAP group while 17 (34%) and 20(40%) were diagnosed
as T-NHL in GDP and DHAP groups.
According to response to previous therapy, 14(28%) were refrac-
tory to treatment in both groups, 23 patients (46%) and 20 (40%)
had a relapse within less than one year in GDP and DHAP groups
and 13(26%) and 16(32%) had a relapse more than one year in
GDP and DHAP groups respectively. None of the patients in both
groups had received Rituximab as a part of primary therapy due
to high cost.
Overall response to treatment was observed in 35 patients
(70%) who received GDP and 32 patients (64%) who received DHAP.
Partial response was observed in 40% and 36% of patients receiving
GDP and DHAP while complete response was observed in 30% and
28% of patients in GDP and DHAP groups. However, there was no
statistical significance difference between both groups regarding
overall, partial or complete response with p-values 0.5, 0.6 and
0.7 respectively (Table 2). 5 patients (10%) progressed on treatment
with GDP and 8 patients (16%) progressed on treatment with DHAP
with no statistical difference.
Regarding toxicity, there was no statistical difference between
both groups except in episodes of febrile neutropenia which
occurred in 36% and 60% of patients receiving GDP and DHAP with
p-value 0.04 (Table 3). Red cell transfusions were needed in 15% of
patients receiving GDP and 25% in patients receiving DHAP while
platelet transfusions were needed in 12% and 15% of patients
Table 3










Anemia 29 (58%) 44 (62.9%) 0.8
Anaemia (III–IV) 8 (16%) 12 (24%) 0.3
Neutropenia 20 (40%) 35 (70%) <0.05
Neutropenia (III–IV) 15 (30%) 30 (60%) 0.003
Thrombocytopenia 25 (50%) 28 (56%) 0.3
Thrombocytopenia (III–IV) 6 (12%) 8 (16%) 0.5
Febrile Neutropenia (III–IV) 18 (36%) 30(60%) <0.05
Gastrointestinal effects
Nausea (I–II) 26 (52%) 31 (62%) 0.6
Vomiting (I–II) 27 (58%) 26 (52%) 0.8
Diarrhea (I–II) 15 (30%) 22 (44%) 0.1
Renal toxicity
(I–II) 18 (36%) 20 (40%) 0.6
Neurological toxicity (I–II)
(mood changes, restless, sleeping
problems, unsteadiness, sensory
neural changes)




16 (32%) 20 (40%) 0.4
Ototoxicity
(I–II) 6 (12%) 10 (20%) 0.2
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interrupted treatment while 10 patients (20%) receiving DHAP
had interrupted treatments and all due to episodes of febrile
neutropenia.
According to quality of life assessment, there was statistically
significant difference between both groups where 20 patients
(40%) and 8 patients (16%) were improved in GDP and DHAP
groups, 19 patients (38%) and 16 (32%) were stable in GDP and
DHAP while, 11 patients (22%) and 26(52%) got worse during treat-
ment with GDP and DHAP with p-value <0.01 (Table 4).
With a median follow up of patients of 14 months (2–24
months), there was no statistical significant difference between
both groups regarding overall survival (OS) which was 30% and
25% in GDP and DHAP (p-value 0.4) Fig. 1. Also there was no statis-
tical difference between both groups in progression free survival
(PFS) which was 18% for GDP and 15% for DHAP (p value 0.8)
(Fig. 2).4. Discussion
Although salvage chemotherapy followed by ASCT is the stan-
dard of care in relapsed/refractory NHL,7 in our country, due to lim-
ited resources, not all cases have that option. They only receive
salvage chemotherapy.
So, in this study we tried to find a salvage regimen that has a
low toxicity profile and better quality of life to be provided to this
group of patients with poor prognosis.Table 4
Quality of life assessment.
GDP group (n = 50) DHAP group (n = 50) P value
QoL assessment
Improved 20 (40%) 8 (16%) <0.05
Stable 19 (38%) 16 (32%) <0.05
Worse 11 (22%) 26 (52%) <0.05DHAP regimen was used depending on the synergy demon-
strated between cisplatin and cytarabine and it became widely
used as a second line treatment in patients with relapsed or refrac-
tory lymphoma and was used as a standard treatment in the study
done by Philip et al.7
Gemcitabine is a pyrimidine antimetabolite which have struc-
tural similarities with cytarabine and is taken into cells more effec-
tively. Gemcitabine containing regimens show activity and synergy
and are used in relapsed refractory lymphoma.8
This study included 100 NHL patients equally divided into 2
groups, one receiving GDP and the other receiving DHAP regimens.
The primary endpoint in our study was the rate of response to
treatment. Overall response was observed in 70% and 64% of
patients receiving GDP and DHAP regimens with no statistical sig-
nificant difference between both groups. These results correlated
with study done by Crump M. et al.9 who also found no statistical
difference between patients receiving GDP and DHAP Their study
included 619 patients with relapsed and refractory B &T cell-
NHL but most patients in that study proceeded to ASCT after 2
cycles of salvage chemotherapy. They observed an ORR of 45% in
GDP group and 44% in DHAP. Our results are slightly higher may
be due to larger number of high risk patients in their study.
Another study done by Ismaeil et al.10 found no significant dif-
ference between both regimens after 6 cycles of treatment. They
included 62 patients with relapsed or refractory NHL and they
observed an ORR of 67.6% in GDP and 65% in DHAP group. How-
ever, that study only included patients with relapsed or refractory
diffuse large B cell lymphoma (DLBCL).
Many other salvage chemotherapy regimens have been used in
this group of patients with relapsed or refractory lymphoma and
they resulted in good ORR as ICE and ESHAP regimens but they
were associated a high toxicity profile with increased hospitaliza-
tion rates and red cell and platelet transfusions.3
Regarding toxicity profile, our study found no significant differ-
ence between both regimens in grade III–IV adverse events except
in episodes of febrile neutropenia which occurred in 36% of
patients in GDP group and 60% of patients in DHAP group (p-
value 0.04). This correlated with results of Crump et al.9 who found
no significant difference between both groups regarding toxicity
except for nausea and febrile neutropenia. However, Ismaiel et al.10
found significant difference between both groups in febrile neu-
tropenia, infection and stomatitis.
Hematologic toxicity remains a concern during treatment with
second line chemotherapy regimens. In this study red cell transfu-
sions were needed in 15% of patients receiving GDP and 25%
receiving DHAP which is considered low when compared to other
regimens as ICE (35%)11 or mini BEAM (60%).12 Fan et al observed
the need of red cell transfusions in 9.2% of patients receiving
GDP and platelet transfusions in 6.6% of patients.13 In this study,
platelet transfusions were needed in 12% and 15% in GDP and
DHAP groups compared to 16.5% and 78% in ICE11 & mini BEAM.12
Crump et al observed the need for platelet transfusions in 18% and
32% of patients receiving GDP and DHAP.9
According to quality of life assessment, GDP was associated
with improved quality of life than DHAP and the difference was
highly significant.
Rituximab, a monoclonal antibody directed against CD20 exerts
its antineoplastic effects through antibody dependant cellular
cytotoxicity which results in decreased cellular proliferation. Add-
ing Rituximab to different salvage chemotherapy regimens as
DHAP or ICE has resulted in increased rates of complete remission
and better progression free survival in patients who did not receive
this drug in their primary regimen protocol. However, data regard-
ing retreatment with rituximab are limited as a proportion of
patients may develop resistance to the drug.3
Fig. 2. Progression free survival.
Fig. 1. Overall survival.
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vage treatment in patients with relapsed or refractory NHL with
lower toxicity profile and better quality of life than DHAP but can-
not be used as a standard of care without ASCT.
Limitations
The study has some limitations as small number of patients and
unavailability of rituximab either in primary or salvage regimens.
Recommendations
Trials with larger number of patients and longer follow up are
recommended.
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